EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma

Brad S Kahl iD, Opeyemi A Jegede iD, Christopher Peterson, Lode J Swinnen, Thomas M Habermann, Stephen J Schuster, Matthias Weiss iD, Paul A Fishkin, Timothy S Fenske iD, Michael E Williams iD

Journal of Clinical Oncology · 01.03.2024 · 42 (7) · 774-778

DOI: 10.1200/jco.23.01912 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2024. Verfasst von Brad S Kahl und 9 weiteren Autor:innen. Beteiligte Einrichtung: Washington University School of Medicine, St Louis, MO. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antineoplastic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In 2003, the Eastern Cooperative Oncology Group initiated a randomized phase III clinical trial (E4402) comparing two different rituximab dosing strategies for patients with previously untreated low–tumor burden follicular lymphoma. Rituximab-responsive patients (n = 299) were randomly assigned to either a retreatment rituximab (RR) strategy or a maintenance rituximab (MR) strategy. Each dosing strategy was continued until treatment failure. The primary end point of the study was time to treatment failure (TTF). In the original report, there was no difference in TTF between the two dosing strategies. Here, we report on the long-term outcomes for secondary end points of time to first cytotoxic therapy, duration of response, and overall survival (OS). At 7 years, 83% of MR patients had not required first chemotherapy compared with 63% of RR patients (hazard ratio, 2.37 [95% CI, 1.5 to 3.76]). At 7 years, 71% of MR remained in their first remission compared with 37% of RR patients. Despite the improved first remission length with MR, there was no difference in OS at 10 years (83% v 84%). With mature long-term data, we confirm that prolonged maintenance rituximab does not confer an OS advantage in low–tumor burden follicular lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAntineoplastic AgentsHumansRituximabFollow-Up StudiesTumor BurdenAntineoplastic Combined Chemotherapy Protocols

Substanzen

RituximabAntineoplastic Agents

Autor:innen und Institutionen

  • Washington University School of Medicine, St Louis, MO.
  • Dana Farber Cancer Institute, Boston, MA.
  • Aspirus Regional Cancer Center, Wausau, WI.
  • Johns Hopkins Cancer Center, Baltimore, MD.
  • Mayo Clinic, Rochester, MN.
  • University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Brad S Kahl, Opeyemi A Jegede, Matthias Weiss, Timothy S Fenske, Michael E Williams

Förderung

  • NCI NIH HHS

Zitieren

APA

Kahl, B. S., Jegede, O. A., Peterson, C., Swinnen, L. J., Habermann, T. M., Schuster, S. J., Weiss, M., Fishkin, P. A., Fenske, T. S., & Williams, M. E. (2024). Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma. Journal of Clinical Oncology, 42(7), 774-778. https://doi.org/10.1200/jco.23.01912

Vancouver

Kahl BS, Jegede OA, Peterson C, Swinnen LJ, Habermann TM, Schuster SJ, et al. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma. Journal of Clinical Oncology. 2024;42(7):774-778. doi:10.1200/jco.23.01912

BibTeX
@article{Kahl2024,
  author = {Kahl, Brad S and Jegede, Opeyemi A and Peterson, Christopher and Swinnen, Lode J and Habermann, Thomas M and Schuster, Stephen J and Weiss, Matthias and Fishkin, Paul A and Fenske, Timothy S and Williams, Michael E},
  title = {Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {7},
  pages = {774--778},
  doi = {10.1200/jco.23.01912}
}
Kostenlos starten →